A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)

AIDS Research and Human Retroviruses

Volumn 18, Issue 10, 2002, Pages 699-704

  Pollard, Richard B ^a   Tierney, Camlin ^b   Havlir, Diane ^c   Tebas, Pablo ^d   Fox, Lawrence ^e   Smeaton, Laura ^b   Richman, Douglas ^c,f   Friedland, Gerald H ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RNA, VIRAL; STAVUDINE; ZIDOVUDINE;

EID: 0036063917     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202760072311     Document Type: Article

References (11)

1. Biologic effects and safety of stavudine: Overview of phase I and II clinical trials
2. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
3. In vivo antagonism with zidovudine plus stavudine combination therapy
4. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro
5. Evaluation of the combination effect of different antiviral compounds against HIV in vitro
6. Cellular pharmacology of 2′, 3′-dideoxy-2′, 3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
7. Drug interactions with zidovudine phosphorylation in vitro
8. Effects of drugs on 2′, 3′-dideoxy-2′, 3′-didehydrothymidine phosphorylation in vitro
9. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
10. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
11. 3